Precision Oncology Drug Shows Power Of Cancer Genomics

  The key to the positive results is molecular matching. Patients received larotrectinib, a TRK inhibitor, only if their cancers were marked by a switch…It’s a perfect example of how precision medicine can benefit patients with rare conditions.

The Big News For Sickle Cell Anemia Is Not Gene Therapy

Blood specialists reported on practice-changing studies for sickle cell disease, including a large study of bone marrow transplant from matched sibling donors. A preliminary report looked at effects of GBT440, a novel oral agent that augments hemoglobin’s binding to oxygen.

In A First, Kidney Cancer Drug Extends Survival

Taken together, the findings raise many possibilities – and questions about strategy, and expense – for testing and prescribing new small drugs and immune-targeting antibodies to patients with kidney and, potentially, other advanced cancer forms.